Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
Joosje C BaltussenSimon P MooijaartAnnelie J E VulinkDanny HoutsmaWendy M Van der DeureElsbeth M WestermanHendrika M OosterkampLeontine E A M M SpieringsFrederiek van den BosNienke A de GlasJohanneke E A PortieljePublished in: Breast cancer research and treatment (2024)
Although grade 3-4 toxicity and dose reductions occurred frequently, most were expected and managed by dose reductions, showing that palbociclib is generally well tolerated and thus represents a valuable treatment option in the older population.